Salute e Benessere

Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology…

INGELHEIM, Germany, September 03, 2024– Boehringer Ingelheim today said it has acquired Saiba Animal Health AG, a company focused on the development of novel therapeutic medicines to address chronic diseases in pets. With the acquisition, Boehringer Ingelheim strengthens its animal health research and development (R&D) pipeline, specifically in the fast-growing pet therapeutics category. As life expectancy for pets increases, so does the need for effective treatment of debilitating...

QIAGEN N.V. launches non-US offering of net share settled convertible bonds

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. VENLO, The Netherlands, Sept.03, 2024(GLOBE NEWSWIRE) -- The Managing Board and Supervisory Board of QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("...

Tethis S.p.A. Collaborates with Weill Cornell Medicine to Advance Cellular…

The Cristofanilli lab will analyze the isolated plasma samples for cell-free DNA (cfDNA), while Tethis scientists will examine the isolated cells for circulating tumor cells (CTCs). The scientists will combine their results and examine them in the light of how the people being treated actually fared, and will publish the results together. The results could guide individualized treatment for people with early-stage breast cancer in the future. The Cristofanilli lab will analyze the isolated...

New European Customer Orders Nexstim NBS System 5

Press release, Helsinki, 3 September 2024 at 9 AM (EEST) New European Customer Orders Nexstim NBS System 5 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a new European customer through a distributor.The Nexstim Navigated Brain Stimulation (NBS) System 5 is the only FDA-cleared and CE-marked navigated TMS (Transcranial Magnetic Stimulation) system for pre-operative mapping of the motor and speech cortices of the brain.Mikko...

CMR Surgical Strengthens Senior Team

CMR Surgical Strengthens Senior Team Markus Bauman, seasoned senior executive has been appointed Chief Legal & Business Affairs Officer and will join CMR's executive leadership teamMichelle Paknad, appointed Senior Vice President, Global Business Development, brings a wealth of commercial experience in the soft-tissue surgical robotics industry Cambridge, UK – 3 September 2024, 07:00 (BST).CMR Surgical (CMR or 'the Company'), the global surgical robotics business, today...

ONWARD® Medical and Partners Awarded Christopher & Dana Reeve Foundation Grant…

Grant will enable ONWARD Medical, CEA-Clinatec and .NeuroRestore to evaluate the use of the ONWARD ARC-BCI™ System to restore thought-driven movement of the hands and arms after spinal cord injury (SCI) The ongoing early feasibility clinical study is also supported by the European Innovation Council under theReverse Paralysisproject. The first study participant was implanted with the investigational ARC-BCI System in August 2023. The Reeve Foundation's $1.1 million grant to study...

BinSina Pharmacy invites the UAE to celebrate 59 years of well-being together

Founded in 1965, BinSina Pharmacy has been an integral part of the UAE's healthcare landscape for nearly six decades, bringing healthy, beautiful living to people in the UAE and beyond. Over the years, the renowned pharmacy chain has grown to encompass a network of over 150 stores plus an expansive e-commerce presence, offering a comprehensive range of health and beauty products. Founded in 1965, BinSina Pharmacy has been an integral part of the UAE's healthcare landscape for nearly six...

Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme…

VLA15-221 Phase 2 study: strong immune response shown one month after a second booster dose (month 31) in pediatric and adult populationsSignificant anamnestic antibody response observed across all six serotypes, consistent with previous resultsFavorable safety profile of VLA15 observed in all age groups and for all vaccinationsSaint-Herblain (France) and New York, NY, September 3, 2024– Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. (NYSE: PFE) announced...

CARBIOS appoints Tommy Maussin as Chief Marketing Officer and Executive…

Clermont-Ferrand (France), 3 September 2024 (06:45 CET). CARBIOS, (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, announces the appointment of Tommy Maussin as its Chief Marketing Officer, effective 2 September 2024. His mission involves developing and overseeing CARBIOS' global marketing and sales activities with brands across various industries, including packaging,...

NRG Fusion Market to Grow at a CAGR of 15% Due to Expected First Launch of…

Key Takeaways from the NRG Fusion Market Report Key Takeaways from the NRG Fusion Market Report Discover which therapies are expected to grab the NRG fusion market share @NRG Fusion Market Report NRG Fusion Market Dynamics NRG fusions have been found inmore than 10types of solid tumors, suggesting they are a promising target for a broad, tumor-agnostic therapeutic approach. Increasing awareness and research in this area make it an appealing opportunity for major industry...

Global Cancer Monoclonal Antibodies Market to Cross ~USD 157 Billion Mark by…

Key Takeaways from the Cancer Monoclonal Antibodies Market Report Key Takeaways from the Cancer Monoclonal Antibodies Market Report To read more about the latest highlights related to the cancer monoclonal antibodies market, get a snapshot of the key highlights entailed in the Global Cancer Monoclonal Antibodies Market Report Cancer Monoclonal Antibodies Overview Monoclonal antibodies (mAbs) have revolutionized cancer treatment by offering highly targeted therapies that...

Roche's PIASKY Approval for Paroxysmal Nocturnal Hemoglobinuria Treatment Will…

In 2023, the Paroxysmal Nocturnal Hemoglobinuria diagnosed prevalent cases were ~12,000 cases in the 7MM, which might reach ~13,000 cases by 2034. In the 7MM, the highest number of paroxysmal nocturnal hemoglobinuria diagnosed prevalent cases were observed in the US. In 2023, the Paroxysmal Nocturnal Hemoglobinuria diagnosed prevalent cases were~12,000cases in the 7MM, which might reach~13,000cases by 2034. In the 7MM, the highest number of paroxysmal nocturnal hemoglobinuria diagnosed...

Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch…

Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device FDA regulatory submission for the Company's Genio® device is complete, U.S. approval on track for the end of 2024U.S. commercial launch, expected at the beginning of 2025, fully funded with over €85 million in new capital raised Nyxoah – NASDAQ Closing Bell Ceremony 29 août 2024Mont-Saint-Guibert, Belgium – September 2, 2024 10:05pm CET / 4:05PM ET – Nyxoah SA...

Trading by management and close relations of management

Please read the full announcement in PDF Attachment 2024_31_Trading_By_Management

Trading by management and close relations of management

Please read the full announcement in PDF Attachment 2024_30_Trading_By_Management

Amended terms of Idorsia's 2024 convertible bonds become effective

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – September 2, 2024Idorsia Ltd (SIX: IDIA) today announced that following the expiry of the appeal period – during which no appeal was filed – the amended terms of Idorsia's outstanding convertible bonds, originally maturing on July 17, 2024 (ISIN: CH0426820350) (the Bonds) have become effective.The cut-off date in respect of the consent fee is today, which means that bondholders holding the Bonds on – or who have...

Non-invasive Prenatal Testing (NIPT) Market worth $14.1 billion by 2029 driven…

Browse in-depth TOC on "Non-invasive Prenatal Testing (NIPT) Market" Browse in-depth TOC on "Non-invasive Prenatal Testing (NIPT) Market" 506 - Tables 63 - Figures 370 - Pages Illumina, Inc.: Pioneering Genetic Analysis Solutions Illumina, Inc. (US) leads the molecular diagnostics space with integrated systems for analyzing genetic variation and biological functions. The company offers a comprehensive range of products, including integrated systems, consumables, and...

Seegene and Springer Nature Launch 'Nature Awards MDx Impact Grants' to Innovate…

Together, Seegene and Springer Nature launched 'Nature Awards MDx Impact Grants in partnership with Seegene', a new project for the development of diagnostic assays. The program empowers researchers worldwide to develop innovative diagnostic assays using Seegene's advanced multiplex PCR technology. Together, Seegene and Springer Nature launched 'Nature Awards MDx Impact Grants in partnership with Seegene', a new project for the development of diagnostic assays. The program empowers…

Global Heart Hub's Insights from Patients living with Elevated Cholesterol…

Participants have highlighted the importance of personalised care plans in managing hypercholesterolemia. Using simple language and clear explanations of the risks associated with unmanaged LDL-C cholesterol level encourages patients to take their health seriously. A collaborative and supportive approach between HCPs and patients is needed to develop care plans, considering individual circumstances and lifestyle factors, ensuring realistic and measurable goals. Discussions on treatment options…

Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK…

TGRX-326 is a third-generation anaplastic lymphoma kinase (ALK) inhibitor independently developed by TargetRx. It is a potent and highly selective small molecule inhibitor that targets ALK and c-ROS proto-oncogene 1 (ROS1) receptor tyrosine kinases (RTKs). This inhibitor holds significant therapeutic potential for ALK/ROS1 fusion gene-positive non-small cell lung cancer (NSCLC) patients, especially those with multiple ALK-resistant mutations, including G1202R. TGRX-326 is a third-generation...

Trading in GN Store Nord shares by board members, executives and associated…

GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN Store Nord and/or persons closely associated with them. Details of the person discharging managerial responsibilities/person closely associated NameJukka Pekka Pertola Reason for the notification Position/statusChair of the Board of DirectorsInitial...

Buyback of Class B shares in Essity during week 35, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...

New US Consensus Report supports Nevisense

"I am so excited that this renowned panel of leading dermatologists has endorsed Nevisense as an important tool for early detection of melanoma. This is a significant step forward for SciBase in our US commercialization process," says Pia Renaudin, CEO of SciBase. " I am so excited that this renowned panel of leading dermatologists has endorsed Nevisense as an important tool for early detection of melanoma. This is a significant step forward for SciBase in our US commercialization…

Myocene Helps the French Handball Team

The innovative device developed by Myocene represents a radical change in the management of fatigue and recovery in sportspeople, making it possible for the first time to quantify it objectively and very precisely. It calculates the exact value of the muscular fatigue index in two minutes. The solution uses a dedicated algorithm to analyze very precise measurements obtained using a specific sensor and high-precision control of muscle contraction. It can be used both indoors and out, helping...

Altri Comunicati